Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ADXS-503 |
Synonyms | |
Therapy Description |
ADXS-503 is an immunotherapy based on a Listeria monocytogenes strain expressing tumor-specific hotspot antigens, including KRAS G12D, which may result in increased anti-tumor immune response and decreased tumor growth (Cancer Res 2018; 78 (13 Suppl):Abstract nr LB-149). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ADXS-503 | ADXS-HOT|ADXS503|ADXS 503 | ADXS-503 is an immunotherapy based on a Listeria monocytogenes strain expressing tumor-specific hotspot antigens, including KRAS G12D, which may result in increased anti-tumor immune response and decreased tumor growth (Cancer Res 2018; 78 (13 Suppl):Abstract nr LB-149). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03847519 | Phase Ib/II | ADXS-503 + Pembrolizumab ADXS-503 | Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer | Completed | USA | 0 |